Toshitaka Nakamura - Concepedia

Author

Toshitaka Nakamura

University of Occupational and Environmental Health Japan ORCID

Also Known As

For the MOVER Study Group, H. Saito, Masayuki Sumida, Sei Haga, T NAKAMURA, T Nakamura, T. Nakamura, TOSHITAKA NAKAMURA, Tadashi Nakamura, Toshitaka Dr. Nakamura

373

Publications

13.2K

Citations

H-Index

182

Concepts

All Affiliations

University of Occupational and Environmental Health Japan Kawasaki Medical School The University of Tokyo Nagasaki University Tottori University

About

Toshitaka Nakamura is an author at University of Occupational and Environmental Health Japan specializing in medicine, osteoporosis, and orthopaedics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	47	135	6.5K
2	Health Sciences	29	42	2.2K
3	Engineering	15	16	1K
4	Education	2	2	57
5	Natural Sciences	1	1	18

Toshitaka Nakamura

220

Publications

12.7K

Citations

H-Index

Page 1

	Year	Citations
Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation Aldemar Montero, Yosuke Okada, Masato Tomita, Journal of Clinical Investigation	2000	470
Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary Hajime Orimo, Toshitaka Nakamura, Takayuki Hosoi, Archives of Osteoporosis	2012	352
Holocene East Asian monsoonal precipitation pattern revealed by grain-size distribution of core sediments of Daihai Lake in Inner Mongolia of north-central China Yongbo Peng, Jianzhong Xiao, Toshitaka Nakamura, Earth and Planetary Science Letters HydrometeorologyClimatologyHoloceneEngineeringGeomorphology	2005	349
Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk Toshitaka Nakamura, Toshitsugu Sugimoto, Tetsuo Nakano, The Journal of Clinical Endocrinology & Metabolism	2012	254
Effects of 1?-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis H. Orimo, Masataka Shiraki, Yujiro Hayashi, Calcified Tissue International Bone DiseaseBone HealthPostmenopausal OsteoporosisVertebral Fractures-Hydroxyvitamin D3	1994	224
Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™) Saeko Fujiwara, Toshitaka Nakamura, H. Orimo, Osteoporosis International	2008	185
A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures — A randomized, active comparator, double-blind study Toshio Matsumoto, Masako Ito, Yasufumi Hayashi, Bone	2011	177
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos, The Lancet Diabetes & Endocrinology Bone DiseaseOsteopathyLoft Extension StudyMedicineGynecology	2019	164
<i>Clinical Trials Express:</i>Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT) Toshitaka Nakamura, Toshio Matsumoto, Toshitsugu Sugimoto, The Journal of Clinical Endocrinology & Metabolism	2014	162
Intravenous Pamidronate Prevents Femoral Bone Loss and Renal Stone Formation During 90-Day Bed Rest Yukiko Watanabe, Hiroshi Ohshima, Koh Mizuno, Journal of Bone and Mineral Research	2004	161

Page 1